Sharemaestro company-news research for ProQR Therapeutics BV (PRQR), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest PRQR news and sentiment
ProQR Therapeutics BV
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
13 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone44/100
→
Published 30-day score50/100
Latest source headline
FY2028 Earnings Estimate for PRQR Issued By HC Wainwright
MarketBeat · 05 Oct 2026 05:28
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
13 current stories are mapped specifically to PRQR.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.008.
Confidence is 16/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news13 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
14 Sep29 Sep13 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.008 after freshness weightingSource breadth20
1 independent publishersCompany relevance100
share tied directly to this companyFreshness17
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202649USD 1.63-0.3%
02 Oct 202647USD 1.635-0.9%
25 Sep 202650USD 1.65-9.8%
18 Sep 202650USD 1.83-1.6%
11 Sep 202651USD 1.86-10.1%
04 Sep 202653USD 2.07-9.6%
28 Aug 202656USD 2.29-2.1%
21 Aug 202660USD 2.34+21.9%
Provisional evidence
News subjects
What is shaping the score
Analyst action496 stories · 46%
Market update505 stories · 38%
Earnings472 stories · 15%
Source mix
Where the evidence comes from
MarketBeat475 stories · 38%
FinancialContent502 stories · 15%
Seeking Alpha501 stories · 8%
Investing.com Nigeria501 stories · 8%
GuruFocus501 stories · 8%
TradingView501 stories · 8%
Stock Titan501 stories · 8%
Recurring subjects
Subjects appearing most often
Life Sciences12Earnings8Financial Markets7Finance3Technology1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral13 Oct 12:34
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Oct 12:34 | 50 | +2 | 17/100 (-5) | 13 (-5) | Provisional |
| 05 Oct 23:59 | 48 | +0 | 22/100 (-4) | 18 (+1) | Provisional |
| 03 Oct 23:59 | 48 | +1 | 26/100 (-3) | 17 (+1) | Provisional |
| 02 Oct 23:59 | 47 | +0 | 29/100 (-4) | 16 (+1) | Provisional |
| 01 Oct 23:59 | 47 | -3 | 33/100 (+33) | 15 (+4) | Provisional |
| 30 Sep 23:59 | 50 | +0 | 0/100 (0) | 11 (0) | Insufficient |
| 27 Sep 23:59 | 50 | +0 | 0/100 (0) | 11 (0) | Insufficient |
| 23 Sep 23:59 | 50 | -1 | 0/100 (-17) | 11 (-15) | Insufficient |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 13 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action1 story
100.0%0.0%
Each side uses the same scale: 0–100.0% of the retained directional evidence.
Where the influence comes from
100.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
EarningsNot used in direction
FY2028 Earnings Estimate for PRQR Issued By HC Wainwright
HC Wainwright has revised its FY2028 earnings per share estimate for ProQR Therapeutics (NASDAQ:PRQR) to a loss of $0.37, a reduction from its prior forecast of a $0.27 loss, while maintaining a "Buy" rating and an $8.00 price target. The biopharmaceutical company recently reported a narr…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
HC Wainwright has revised its FY2028 earnings per share estimate for ProQR Therapeutics (NASDAQ:PRQR) to a loss of $0.37, a reduction from its prior forecast of a $0.27 loss, while maintaining a "Buy" rating and an $8.00 price target. The biopharmaceutical company recently reported a narrower-than-expected quarterly loss of $0.09 per share and revenue of $10 million, significantly beating analyst estimates. Analyst sentiment generally remains positive with a "Moderate Buy" consensus, and company insiders have recently purchased a substantial amount of shares.
- Published
- 05 Oct 2026 05:28
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Press Releases about ProQR Therapeutics N.V. - Ordinary Shares (Nasdaq:PRQR)
This article compiles various press releases from ProQR Therapeutics N.V. (Nasdaq: PRQR) covering a range of corporate and clinical updates. Key announcements include leadership appointments, initiation of clinical trials for AX-0811, positive Phase 1 data for AX-0810, financial results, …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article compiles various press releases from ProQR Therapeutics N.V. (Nasdaq: PRQR) covering a range of corporate and clinical updates. Key announcements include leadership appointments, initiation of clinical trials for AX-0811, positive Phase 1 data for AX-0810, financial results, and participation in investor conferences. The updates highlight the company's progress in advancing its proprietary ADAR-mediated Axiomer™ RNA editing technology platform for transformative RNA therapies.
- Published
- 03 Oct 2026 07:32
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsLife Sciences
—Unscored
Market updateNot used in direction
ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Stock Price, News, Quote & History
ProQR Therapeutics N.V. (PRQR) is a biotechnology company focused on developing RNA-based therapies for genetic disorders. The article provides current stock information, including a last price of $1.6350, and highlights recent news such as the first human validation of its RNA editing pl…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ProQR Therapeutics N.V. (PRQR) is a biotechnology company focused on developing RNA-based therapies for genetic disorders. The article provides current stock information, including a last price of $1.6350, and highlights recent news such as the first human validation of its RNA editing platform in liver disease and new executive appointments. It also details past press releases regarding clinical trials, financial results, and investor conferences.
- Published
- 02 Oct 2026 14:31
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
ProQR Therapeutics announced the first human validation of its RNA-editing platform for liver disease, showing dose-dependent target engagement for its AX-0810 candidate. The treatment, aimed at cholestatic liver diseases like pediatric biliary atresia, demonstrated no serious adverse eve…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ProQR Therapeutics announced the first human validation of its RNA-editing platform for liver disease, showing dose-dependent target engagement for its AX-0810 candidate. The treatment, aimed at cholestatic liver diseases like pediatric biliary atresia, demonstrated no serious adverse events and increased plasma bile acids. ProQR expects data from its next-generation candidate, AX-0811, in early 2027, which is designed for greater potency and durability.
- Published
- 02 Oct 2026 08:02
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Life Sciences
—Unscored
Analyst actionNot used in direction
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow (NASDAQ:PRQR) 2026-09-30
ProQR Therapeutics N.V. (PRQR) released a slide deck for a shareholder/analyst call held on September 30, 2026. The article highlights that the content was published in conjunction with this event and was prepared by Seeking Alpha's transcripts team.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ProQR Therapeutics N.V. (PRQR) released a slide deck for a shareholder/analyst call held on September 30, 2026. The article highlights that the content was published in conjunction with this event and was prepared by Seeking Alpha's transcripts team.
- Published
- 01 Oct 2026 17:31
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
Analyst actionNot used in direction
ProQR Therapeutics' (PRQR) "Buy" Rating Reiterated at Chardan Capital
Chardan Capital has reiterated its "buy" rating for ProQR Therapeutics (NASDAQ:PRQR), setting a $3.00 price target that suggests an 80.72% upside. Other analysts have also issued ratings, contributing to an average "Moderate Buy" rating and an average target price of $7.60 for the biophar…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Chardan Capital has reiterated its "buy" rating for ProQR Therapeutics (NASDAQ:PRQR), setting a $3.00 price target that suggests an 80.72% upside. Other analysts have also issued ratings, contributing to an average "Moderate Buy" rating and an average target price of $7.60 for the biopharmaceutical company. Recent insider activity shows significant share purchases by the company's director and CEO.
- Published
- 01 Oct 2026 12:31
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
44/100 tone
HC Wainwright has lowered its price target for ProQR Therapeutics (NASDAQ:PRQR) to $8.00 while maintaining a "buy" rating, indicating a potential upside of 381.93%. Other analysts have also issued reports on the biopharmaceutical company, resulting in an average rating of "Moderate Buy" a…
100% of directional evidence
Low story strength
Scoring detailsDirect company coverage
HC Wainwright has lowered its price target for ProQR Therapeutics (NASDAQ:PRQR) to $8.00 while maintaining a "buy" rating, indicating a potential upside of 381.93%. Other analysts have also issued reports on the biopharmaceutical company, resulting in an average rating of "Moderate Buy" and an average price target of $7.60. The company recently reported better-than-expected earnings and saw significant insider buying.
- Published
- 01 Oct 2026 12:31
- News subject
- Analyst action
- Why this score
- Analyst downgrade
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 100% of directional evidence · 12.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
H.C. Wainwright cuts ProQR stock price target on execution risks By Investing.com
H.C. Wainwright has reduced its price target for ProQR Therapeutics N.V. (NASDAQ:PRQR) to $8.00 from $12.00, citing execution and regulatory risks, despite maintaining a Buy rating. The biotech company, currently trading at $1.66, is burning through cash but holds more cash than debt and …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
H.C. Wainwright has reduced its price target for ProQR Therapeutics N.V. (NASDAQ:PRQR) to $8.00 from $12.00, citing execution and regulatory risks, despite maintaining a Buy rating. The biotech company, currently trading at $1.66, is burning through cash but holds more cash than debt and has liquid assets exceeding short-term obligations. ProQR recently shared positive initial safety data for its AX-0810 drug, and analysts continue to show interest in its innovative therapies.
- Published
- 01 Oct 2026 12:22
- News subject
- Analyst action
- Why this score
- Buy Rating, Analyst downgrade
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
ProQR Therapeutics NV Investor and Analyst Event: NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing Call Transcript
This document is a call transcript from a ProQR Therapeutics NV Investor and Analyst Event focusing on NTCP modulation in biliary atresia through liver-targeted RNA editing. The event includes a formal presentation and a Q&A session, with an emphasis on forward-looking statements and asso…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This document is a call transcript from a ProQR Therapeutics NV Investor and Analyst Event focusing on NTCP modulation in biliary atresia through liver-targeted RNA editing. The event includes a formal presentation and a Q&A session, with an emphasis on forward-looking statements and associated risks. Sarah Keeley, VP of Investor Relations and Corporate Communications, initiated the call.
- Published
- 30 Sep 2026 13:31
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsLife Sciences
—Unscored
Market updateNot used in direction
Price to sales forward of ProQR Therapeutics N.V. – DUS:0PQ
The article focuses on the "Price to sales forward" financial metric for ProQR Therapeutics N.V. (DUS:0PQ), listed on the Dusseldorf Stock Exchange. It appears to be a financial data snippet or a specific page from a financial analysis platform like TradingView, showing a value for this m…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
The article focuses on the "Price to sales forward" financial metric for ProQR Therapeutics N.V. (DUS:0PQ), listed on the Dusseldorf Stock Exchange. It appears to be a financial data snippet or a specific page from a financial analysis platform like TradingView, showing a value for this metric over a certain period. The content primarily lists various navigation and product options available on the platform, suggesting it's part of a larger financial information portal.
- Published
- 27 Sep 2026 18:23
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Hugging Face co-founder joins ProQR (PRQR) to drive AI drug discovery
ProQR Therapeutics N.V. (PRQR) has appointed Chris Hart, PhD, as Chief Data and AI Officer and welcomed Thomas Wolf, PhD, co-founder of Hugging Face, as a strategic AI advisor to its Board. These appointments aim to integrate AI further into the company's drug discovery and development pr…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ProQR Therapeutics N.V. (PRQR) has appointed Chris Hart, PhD, as Chief Data and AI Officer and welcomed Thomas Wolf, PhD, co-founder of Hugging Face, as a strategic AI advisor to its Board. These appointments aim to integrate AI further into the company's drug discovery and development processes using its Axiomer RNA editing platform. ProQR anticipates up to five clinical data readouts across four development programs in the next 12 months, including target-engagement data for its AI-discovered drug AX-0811 expected in early January 2027.
- Published
- 23 Sep 2026 12:13
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life SciencesTechnology
—Unscored
EarningsNot used in direction
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Brokerages
ProQR Therapeutics (NASDAQ:PRQR) has received an average "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $7.50, significantly higher than its current $1.90 opening price. The company surpassed quarterly earnings estimates, reporting a negative EPS of …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ProQR Therapeutics (NASDAQ:PRQR) has received an average "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $7.50, significantly higher than its current $1.90 opening price. The company surpassed quarterly earnings estimates, reporting a negative EPS of $0.09 against an expected negative $0.13, and revenue of $10 million against an anticipated $4.56 million. Insider transactions show executives and directors purchased 600,000 shares worth $988,500 in the last 90 days.
- Published
- 23 Sep 2026 06:13
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
ProQR Therapeutics (Nasdaq:PRQR) - Stock Analysis
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
PRQR news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
10Sep 2026
ProQR Therapeutics has commenced its AX-0811 early-phase clinical trial by administering the RNA editing treatment candidate to the first participant. This study, focusing on NTCP modulation for cholestatic liver diseases like biliary atresia, will evaluate safety, tolerability, pharmacok…
Article detailsHistorical record
ProQR Therapeutics has commenced its AX-0811 early-phase clinical trial by administering the RNA editing treatment candidate to the first participant. This study, focusing on NTCP modulation for cholestatic liver diseases like biliary atresia, will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic biomarkers. Preliminary target-engagement results are expected in early January 2027.
- Published
- 10 Sep 2026 19:34
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Life Sciences
10Sep 2026
ArchivedNeutral tone
ProQR doses first participant in AX-0811 phase 1 trial
ProQR Therapeutics N.V. (NASDAQ:PRQR) has dosed the first participant in its Phase 1 clinical trial of AX-0811. AX-0811 is an investigational RNA editing oligonucleotide designed to treat cholestatic liver diseases, including biliary atresia, and has shown improved potency and longer half…
Article detailsHistorical record
ProQR Therapeutics N.V. (NASDAQ:PRQR) has dosed the first participant in its Phase 1 clinical trial of AX-0811. AX-0811 is an investigational RNA editing oligonucleotide designed to treat cholestatic liver diseases, including biliary atresia, and has shown improved potency and longer half-life in preclinical data compared to AX-0810. The company anticipates releasing Phase 1 target engagement data for the initial two cohorts in early January 2027 and will host an investor event on September 30, 2026, to discuss its development strategy.
- Published
- 10 Sep 2026 02:34
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Life Sciences
09Sep 2026
Article detailsHistorical record
- Published
- 9 Sep 2026 14:23
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
09Sep 2026
ProQR Therapeutics (NASDAQ:PRQR) shares have surpassed their 50-day moving average, reaching $2.11 and closing at $2.05, exceeding the average of $1.92. The company reported better-than-expected quarterly results, with a smaller adjusted loss per share and higher revenue than projected. A…
Article detailsHistorical record
ProQR Therapeutics (NASDAQ:PRQR) shares have surpassed their 50-day moving average, reaching $2.11 and closing at $2.05, exceeding the average of $1.92. The company reported better-than-expected quarterly results, with a smaller adjusted loss per share and higher revenue than projected. Analysts maintain a "Moderate Buy" rating with an average price target of $7.50, and insiders have recently purchased a significant number of shares.
- Published
- 9 Sep 2026 09:30
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
09Sep 2026
ProQR Therapeutics N.V. has announced that the first participant has been dosed in a Phase 1 clinical trial for AX-0811, an AI-discovered RNA editing oligonucleotide designed for cholestatic liver diseases. The company also plans to host a virtual Investor and Analyst educational event on…
Article detailsHistorical record
ProQR Therapeutics N.V. has announced that the first participant has been dosed in a Phase 1 clinical trial for AX-0811, an AI-discovered RNA editing oligonucleotide designed for cholestatic liver diseases. The company also plans to host a virtual Investor and Analyst educational event on September 30, 2026, to discuss NTCP modulation in biliary atresia and the clinical development strategy for AX-0811. Initial target engagement data for AX-0811 are expected in early January 2027.
- Published
- 9 Sep 2026 09:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Life Sciences
03Sep 2026
ArchivedNeutral tone
ProQR to Participate in Upcoming Investor Conferences in September 2026
ProQR Therapeutics N.V. announced its participation in two upcoming investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference. Management will hold one-on-one meetings and a fireside chat to discuss the company's …
Article detailsHistorical record
ProQR Therapeutics N.V. announced its participation in two upcoming investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference. Management will hold one-on-one meetings and a fireside chat to discuss the company's proprietary ADAR-mediated Axiomer™ RNA editing technology platform. Webcast details will be available on ProQR’s website.
- Published
- 3 Sep 2026 04:55
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
29Aug 2026
ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month price target of $7.50. The company recently reported better-than-expected quarterly earnings and revenue. Insiders and institutional investors have shown sign…
Article detailsHistorical record
ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month price target of $7.50. The company recently reported better-than-expected quarterly earnings and revenue. Insiders and institutional investors have shown significant buying activity in the stock.
- Published
- 29 Aug 2026 23:21
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
28Aug 2026
ProQR Therapeutics (NASDAQ:PRQR) saw its share price cross above its 50-day moving average, trading at $2.32 compared to the average of $1.87. This comes amidst positive analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $7.50, and better-than-expecte…
Article detailsHistorical record
ProQR Therapeutics (NASDAQ:PRQR) saw its share price cross above its 50-day moving average, trading at $2.32 compared to the average of $1.87. This comes amidst positive analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $7.50, and better-than-expected quarterly results. Additionally, company insiders have recently purchased 600,000 shares, signaling confidence in the stock.
- Published
- 28 Aug 2026 23:21
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
24Aug 2026
Certain warrants of ProQR Therapeutics N.V. are currently under a lock-up agreement, which began on June 25, 2026, and is set to expire on August 24, 2026. During this period, officers and directors are restricted from directly or indirectly selling, pledging, or otherwise disposing of or…
Article detailsHistorical record
Certain warrants of ProQR Therapeutics N.V. are currently under a lock-up agreement, which began on June 25, 2026, and is set to expire on August 24, 2026. During this period, officers and directors are restricted from directly or indirectly selling, pledging, or otherwise disposing of ordinary shares or convertible securities without prior written consent from BofA Securities, Inc., Evercore Group L.L.C., and Cantor Fitzgerald & Co. This lock-up is designed to manage the sale of company securities by insiders following specific events.
- Published
- 24 Aug 2026 01:14
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
EarningsFinanceFinancial MarketsLife Sciences
22Aug 2026
ProQR Therapeutics has received a Buy rating due to promising phase 1 results for its AX-0810 drug, showing an 8-fold increase in serum bile acids, which suggests potential for treating biliary atresia. The company anticipates several key clinical milestones by early 2027, including full …
Article detailsHistorical record
ProQR Therapeutics has received a Buy rating due to promising phase 1 results for its AX-0810 drug, showing an 8-fold increase in serum bile acids, which suggests potential for treating biliary atresia. The company anticipates several key clinical milestones by early 2027, including full phase 1 data for AX-0810 and results for AX-0811. With strong cash reserves and a partnership with Eli Lilly, ProQR is well-positioned for significant value growth.
- Published
- 22 Aug 2026 07:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
21Aug 2026
Article detailsHistorical record
- Published
- 21 Aug 2026 21:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
21Aug 2026
ArchivedPositive tone
ProQR Therapeutics initiated with a Buy at BofA
Article detailsHistorical record
- Published
- 21 Aug 2026 02:11
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
20Aug 2026
ArchivedNeutral tone
Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ
The article focuses on the "Price to sales forward" financial metric for ProQR Therapeutics N.V., traded on the Frankfurt Stock Exchange under the symbol 0PQ. It appears to be a stub or a section from a larger financial data platform, providing a heading for this specific financial data p…
Article detailsHistorical record
The article focuses on the "Price to sales forward" financial metric for ProQR Therapeutics N.V., traded on the Frankfurt Stock Exchange under the symbol 0PQ. It appears to be a stub or a section from a larger financial data platform, providing a heading for this specific financial data point without presenting the actual numerical values.
- Published
- 20 Aug 2026 23:11
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
20Aug 2026
ArchivedPositive tone
ProQR Therapeutics initiated with a Buy at BofA
Article detailsHistorical record
- Published
- 20 Aug 2026 18:29
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
20Aug 2026
ArchivedPositive tone
PRQR Looks 1.8% Undervalued on GF Value™ at $2.45
Bank of America Securities initiated coverage on ProQR Therapeutics NV (PRQR) with a buy rating and an $8 price target, validating its Axiomer RNA-editing platform. Despite its early development stage, unprofitability, and negative cash flow, the stock is considered moderately undervalued…
Article detailsHistorical record
Bank of America Securities initiated coverage on ProQR Therapeutics NV (PRQR) with a buy rating and an $8 price target, validating its Axiomer RNA-editing platform. Despite its early development stage, unprofitability, and negative cash flow, the stock is considered moderately undervalued by GuruFocus's GF Value™ at $2.45, with strong insider buying indicating management confidence. The company’s GF Score™ of 50/100 highlights strengths in valuation and momentum, balanced by concerns in financial strength.
- Published
- 20 Aug 2026 17:40
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
20Aug 2026
ArchivedPositive tone
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America
Bank of America has initiated coverage on ProQR Therapeutics (NASDAQ:PRQR) with a "buy" rating and an $8.00 price target, suggesting a significant upside. This positive outlook is supported by recent strong quarterly earnings, where ProQR exceeded revenue and EPS expectations, and substan…
Article detailsHistorical record
Bank of America has initiated coverage on ProQR Therapeutics (NASDAQ:PRQR) with a "buy" rating and an $8.00 price target, suggesting a significant upside. This positive outlook is supported by recent strong quarterly earnings, where ProQR exceeded revenue and EPS expectations, and substantial insider stock purchases totaling approximately $988,500. The consensus among analysts remains a "Moderate Buy" with a $7.50 target price.
- Published
- 20 Aug 2026 12:42
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
18Aug 2026
ArchivedNeutral tone
Equities Analysts Set Expectations for PRQR FY2030 Earnings
HC Wainwright has updated its FY2030 earnings per share estimate for ProQR Therapeutics (NASDAQ:PRQR) to $0.20, an increase from $0.18, and reiterated a "Buy" rating. Despite this positive revision, the consensus full-year earnings estimate remains a loss of $0.52 per share. The biopharma…
Article detailsHistorical record
HC Wainwright has updated its FY2030 earnings per share estimate for ProQR Therapeutics (NASDAQ:PRQR) to $0.20, an increase from $0.18, and reiterated a "Buy" rating. Despite this positive revision, the consensus full-year earnings estimate remains a loss of $0.52 per share. The biopharmaceutical company has a "Moderate Buy" consensus rating with an average price target of $7.33, reflecting broad analyst optimism, while recent insider buying highlights confidence in the stock.
- Published
- 18 Aug 2026 13:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
15Aug 2026
ArchivedPositive tone
ProQR Therapeutics (PRQR) Stock Rises On Revenue Surge As Losses Ease
Article detailsHistorical record
- Published
- 15 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
15Aug 2026
ArchivedPositive tone
ProQR Therapeutics (PRQR) Stock Rises On Revenue Surge As Losses Ease
Article detailsHistorical record
- Published
- 15 Aug 2026 02:37
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
15Aug 2026
ArchivedNeutral tone
ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results
Article detailsHistorical record
- Published
- 15 Aug 2026 01:35
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
14Aug 2026
ArchivedNegative tone
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Article detailsHistorical record
- Published
- 14 Aug 2026 13:25
- Catalyst
- Guidance
- Coverage
- Direct company
- Duplicates
- 1 consolidated
14Aug 2026
ArchivedNeutral tone
ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results
Article detailsHistorical record
- Published
- 14 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
13Aug 2026
ArchivedPositive tone
ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates
ProQR Therapeutics NV (NASDAQ: PRQR) reported second-quarter earnings per share that beat analyst estimates by €0.03, coming in at €-0.080 against an estimate of €-0.114. The company's revenue also surpassed expectations, reaching €8.76 million compared to the consensus estimate of €3.97 …
Article detailsHistorical record
ProQR Therapeutics NV (NASDAQ: PRQR) reported second-quarter earnings per share that beat analyst estimates by €0.03, coming in at €-0.080 against an estimate of €-0.114. The company's revenue also surpassed expectations, reaching €8.76 million compared to the consensus estimate of €3.97 million. Despite these positive results, the company's stock price has decreased by 6.68% over the last 12 months, although it has risen by 16.98% in the last 3 months.
- Published
- 13 Aug 2026 18:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 3 consolidated
EarningsFinancial MarketsLife Sciences
13Aug 2026
Article detailsHistorical record
- Published
- 13 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
07Aug 2026
ArchivedNeutral tone
ProQR Therapeutics NV (PRQR) Stock News Today
This article provides current stock information for ProQR Therapeutics NV (PRQR), including its recent trading performance, market capitalization, and links to financial data and analyst ratings. It notes that more news is expected soon for the company. The stock closed at $1.875, down 1.…
Article detailsHistorical record
This article provides current stock information for ProQR Therapeutics NV (PRQR), including its recent trading performance, market capitalization, and links to financial data and analyst ratings. It notes that more news is expected soon for the company. The stock closed at $1.875, down 1.32%.
- Published
- 7 Aug 2026 20:39
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
07Aug 2026
ArchivedPositive tone
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for ProQR Therapeutics NV (PRQR), indicating a current earnings forecast score of 8.67 and a ranking of 74 out of 387 in its industry. Analysts have set an average price target of $9.50 with a "Buy" rating. The article also details expected reven…
Article detailsHistorical record
This article provides an earnings forecast for ProQR Therapeutics NV (PRQR), indicating a current earnings forecast score of 8.67 and a ranking of 74 out of 387 in its industry. Analysts have set an average price target of $9.50 with a "Buy" rating. The article also details expected revenue and EPS for upcoming quarters and highlights past earnings performance.
- Published
- 7 Aug 2026 14:16
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
04Aug 2026
ProQR Therapeutics N.V. (NASDAQ:PRQR) has received an average rating of "Moderate Buy" from analysts, with four out of six recommending a buy. The average 12-month price target is $7.33, significantly higher than the recent share price of $1.71. Despite missing revenue estimates, the comp…
Article detailsHistorical record
ProQR Therapeutics N.V. (NASDAQ:PRQR) has received an average rating of "Moderate Buy" from analysts, with four out of six recommending a buy. The average 12-month price target is $7.33, significantly higher than the recent share price of $1.71. Despite missing revenue estimates, the company met EPS expectations, and insiders have recently increased their holdings, with the CEO and a director purchasing 150,000 shares each.
- Published
- 4 Aug 2026 07:39
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
03Aug 2026
An insider at ProQR Therapeutics N.V. (NASDAQ: PRQR) recently purchased shares valued at $353,960. This transaction was disclosed in a recent SEC filing. ProQR Therapeutics is a biotechnology company focused on developing RNA-based therapeutics for severe genetic disorders.
Article detailsHistorical record
An insider at ProQR Therapeutics N.V. (NASDAQ: PRQR) recently purchased shares valued at $353,960. This transaction was disclosed in a recent SEC filing. ProQR Therapeutics is a biotechnology company focused on developing RNA-based therapeutics for severe genetic disorders.
- Published
- 3 Aug 2026 21:39
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 2 consolidated
FinanceLife Sciences
03Aug 2026
ArchivedNeutral tone
ProQR Therapeutics (PRQR) CEO boosts stake with 200,000-share buy
ProQR Therapeutics N.V. CEO Daniel Anton de Boer recently purchased 200,000 Ordinary Shares at $1.7698 per share, increasing his direct holdings to 500,000 shares. This transaction, categorized as an open market or private purchase, was disclosed in a Form 4 filing and indicates a positiv…
Article detailsHistorical record
ProQR Therapeutics N.V. CEO Daniel Anton de Boer recently purchased 200,000 Ordinary Shares at $1.7698 per share, increasing his direct holdings to 500,000 shares. This transaction, categorized as an open market or private purchase, was disclosed in a Form 4 filing and indicates a positive sentiment from the CEO regarding the company's prospects. The Rule 10b5-1 trading-plan checkbox was not marked for this transaction.
- Published
- 3 Aug 2026 20:39
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
01Aug 2026
ArchivedNeutral tone
ProQR Therapeutics N.V. Revenue Breakdown – NASDAQ:PRQR
ProQR Therapeutics N.V. (NASDAQ: PRQR) generated $19.14 million in revenue last year, with its RNA Based Therapeutics segment being the top performer, contributing $17.95 million. The United States was the primary geographic contributor, also accounting for $17.95 million. This represents…
Article detailsHistorical record
ProQR Therapeutics N.V. (NASDAQ: PRQR) generated $19.14 million in revenue last year, with its RNA Based Therapeutics segment being the top performer, contributing $17.95 million. The United States was the primary geographic contributor, also accounting for $17.95 million. This represents a slight decrease from the previous year's revenue of $20.45 million for both the segment and the country.
- Published
- 1 Aug 2026 07:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to PRQR, but the headline and available text are not mainly about ProQR Therapeutics BV. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of PRQR sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.